IBJNews

Potential Effient rival recommended for approval

Back to TopCommentsE-mailPrintBookmark and Share

Johnson & Johnson and Bayer AG’s blood-thinner Xarelto should be approved to help prevent heart attacks and strokes in patients with a common condition, a U.S. regulatory report recommended.

The drug works in patients with acute coronary syndrome, which occurs when a blood clot blocks blood supply to the heart, Food and Drug Administration staff said Monday in a report ahead of a advisory panel meeting Wednesday on Xarelto. The agency is scheduled to decide on expanding use of the drug by June 29.

If approved for acute coronary syndrome, Xarelto would compete with London-based AstraZeneca Plc’s Brilinta and Indianapolis-based Eli Lilly and Co.’s Effient. Lilly sold about $300 million worth of Effient in 2012.

Acute coronary syndrome accounts for 1.2 million hospitalizations each year, according to New Brunswick, N.J-based J&J. The market for treatments for the condition may total more than $1 billion. The FDA approved Xarelto in November to prevent stroke in patients with irregular heartbeat. The medicine has been on the market since July to prevent blood clots in patients undergoing knee and hip surgeries.

“The benefit risk ratio for Xarelto appears to be favorable, predominantly because there is a reduction in” cardiovascular death “despite an increased risk of major and fatal bleeding,” reviewer Karen Hicks said in the FDA report.

Xarelto given at 2.5 milligrams reduced heart attacks and strokes 15 percent compared with placebo while resulting in a two-fold increase in fatal bleeding and three-fold increases in major bleeding, intracranial hemorrhage, hemorrhagic stroke and minor bleeding that indicated a hemorrhage, according to the report.

Les Funtleyder, a portfolio manager at Miller Tabak & Co., and Tony Butler, an analyst at Barclays Capital Inc. in New York, said they expect Xarelto to gain approval because of its ability to prevent death.

J&J’s drug “will probably be a market leader,” Funtleyder said. “All of these things have bleeding risks.”

J&J owns U.S. rights to the drug while Leverkusen, Germany- based Bayer sells the medicine in Europe. The drug would be taken twice daily in combination with aspirin and Plavix, made by Paris-based Sanofi and New York-based Bristol-Myers Squibb Co.

Xarelto is one of the medicines attempting to replace warfarin, which requires constant monitoring and dose adjustments to keep blood from getting too thin and putting patients at risk of severe bleeding. Xarelto’s sales are expected to reach $799 million in 2015, according to the average of four analysts surveyed by Bloomberg.

New York-based Pfizer Inc. and Bristol-Myers are awaiting a June 28 decision on their blood-thinner Eliquis in patients with an irregular heartbeat. Boehringer Ingelheim Gmbh, a closely held company based in Ingelheim, Germany, won approval in 2010 to sell its blood thinner, Pradaxa, for those patients.

Lilly shares were up 13 cents Monday morning, to $40.56 apiece.
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. The east side does have potential...and I have always thought Washington Scare should become an outlet mall. Anyone remember how popular Eastgate was? Well, Indy has no outlet malls, we have to go to Edinburgh for the deep discounts and I don't understand why. Jim is right. We need a few good eastsiders interested in actually making some noise and trying to change the commerce, culture and stereotypes of the East side. Irvington is very progressive and making great strides, why can't the far east side ride on their coat tails to make some changes?

  2. Boston.com has an article from 2010 where they talk about how Interactions moved to Massachusetts in the year prior. http://www.boston.com/business/technology/innoeco/2010/07/interactions_banks_63_million.html The article includes a link back to that Inside Indiana Business press release I linked to earlier, snarkily noting, "Guess this 2006 plan to create 200-plus new jobs in Indiana didn't exactly work out."

  3. I live on the east side and I have read all your comments. a local paper just did an article on Washington square mall with just as many comments and concerns. I am not sure if they are still around, but there was an east side coalition with good intentions to do good things on the east side. And there is a facebook post that called my eastside indy with many old members of the eastside who voice concerns about the east side of the city. We need to come together and not just complain and moan, but come up with actual concrete solutions, because what Dal said is very very true- the eastside could be a goldmine in the right hands. But if anyone is going damn, and change things, it is us eastside residents

  4. Please go back re-read your economics text book and the fine print on the February 2014 CBO report. A minimum wage increase has never resulted in a net job loss...

  5. The GOP at the Statehouse is more interested in PR to keep their majority, than using it to get anything good actually done. The State continues its downward spiral.

ADVERTISEMENT